Subject category:
Ethics and Social Responsibility
Published by:
IBS Center for Management Research
Length: 13 pages
Data source: Published sources
Share a link:
https://casecent.re/p/62439
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
The case gives an overview on the controversy involving Vioxx, a drug produced by the US-based Merck, a global pharma major. Vioxx was used for the treatment of arthritis and acute pain. The product was promoted aggressively by Merck and had emerged as one of the best selling drugs for Merck within a year of its launch. However, medical experts raised doubts about the cardiovascular risks associated with Vioxx's long-term usage. In the initial years, Merck disagreed with the various medical studies, until its own internal study indicated such cardiovascular risks. Finally, in September 2004, Vioxx was recalled from the market. The case highlights the ethical issues involved in Vioxx's controversy and examines the way Merck handled the entire issue.
Teaching and learning
This item is suitable for postgraduate courses.About
Abstract
The case gives an overview on the controversy involving Vioxx, a drug produced by the US-based Merck, a global pharma major. Vioxx was used for the treatment of arthritis and acute pain. The product was promoted aggressively by Merck and had emerged as one of the best selling drugs for Merck within a year of its launch. However, medical experts raised doubts about the cardiovascular risks associated with Vioxx's long-term usage. In the initial years, Merck disagreed with the various medical studies, until its own internal study indicated such cardiovascular risks. Finally, in September 2004, Vioxx was recalled from the market. The case highlights the ethical issues involved in Vioxx's controversy and examines the way Merck handled the entire issue.